Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (OCUP) on November 20, 2023, with the earliest event reported on that date. The filing discloses the appointment of Joseph Schachle as Chief Operating Officer, effective November 27, 2023. Note: While the request metadata mentions "Opus Genetics, Inc.," the filing text explicitly identifies the registrant as Ocuphire Pharma, Inc., and notes Mr. Schachle's prior employment at Opus Genetics.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the addition of Joseph Schachle to the executive team as Chief Operating Officer. This represents a strategic leadership change following his previous tenure as COO at Opus Genetics, Inc. (October 2021 to March 2023) and subsequent consulting role.
Guidance, Outlook, and Compensation Details
The filing details the terms of Mr. Schachle's employment agreement:
- Base Salary: $400,000 annually, subject to annual review.
- Incentive Compensation: Targeted at 45% of base salary.
- Equity Grant: Nonstatutory stock option to purchase 300,000 shares of common stock under the 2021 Inducement Plan.
- Vesting Schedule: 25% vests on the first anniversary of the grant date; the remaining 75% vests in equal monthly installments over the subsequent 36 months.
- Severance: In the event of termination without Cause or resignation for Good Reason, Mr. Schachle is entitled to 9 months of base salary continuation and COBRA premium reimbursement.
- Other Agreements: Includes standard indemnification, confidentiality, and non-competition agreements.
The filing includes a Regulation FD disclosure referencing a press release issued on November 27, 2023, regarding this appointment.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 300,000 stock options granted to Mr. Schachle in the attached Exhibit 10.1.
- Confirm the definitions of "Cause" and "Good Reason" within the Offer Letter to understand severance triggers.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the appointment not included in the 8-K text.
- Check subsequent filings for any updates to the company's cash position or burn rate, as this filing does not provide liquidity data.